Edwards Lifesciences Corporation $EW Position Trimmed by Equitable Trust Co.

Equitable Trust Co. reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 8.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 68,588 shares of the medical research company’s stock after selling 6,685 shares during the quarter. Equitable Trust Co.’s holdings in Edwards Lifesciences were worth $5,364,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after buying an additional 2,576,383 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Edwards Lifesciences by 4.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after acquiring an additional 264,311 shares during the period. Nuveen LLC acquired a new stake in Edwards Lifesciences in the 1st quarter worth $330,881,000. Invesco Ltd. grew its position in Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after purchasing an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after purchasing an additional 198,882 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Tuesday, July 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research report on Monday, September 22nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Finally, Mizuho raised their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 1.4%

Shares of EW opened at $72.94 on Tuesday. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The company has a market cap of $42.82 billion, a price-to-earnings ratio of 10.49, a PEG ratio of 3.55 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a fifty day moving average price of $77.95 and a two-hundred day moving average price of $76.18.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the firm earned $0.70 EPS. The company’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.